RGNX (Regenxbio) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RGNX Regenxbio Inc RGNX
55 GF Score
Price $12.75
GF Value $14.70
Valuation Modestly Undervalued
! 9 Warning Signs
View Full Analysis

What is Regenxbio Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

RGNX
55GF Score
Regenxbio Inc RGNX
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Regenxbio (RGNX) Overvalued in 2026?

Based on GuruFocus' analysis, Regenxbio stock appears to be undervalued. The current stock price of $12.75 is trading 13.3% below its estimated GF Value™ of $14.70. GuruFocus considers Regenxbio to be Modestly Undervalued.

Key valuation signals for RGNX:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $14.70 vs. price of $12.75 (13.3% below fair value)
  • GF Score™: 55/100 with 9 warning signs

No single metric tells the full story. See the RGNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Regenxbio Business Description

Other Exchanges RB0:Germany
Address 9804 Medical Center Drive, Rockville, MD, USA, 20850
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
55GF Score

Get the complete analysis for RGNX

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.75
Price
$14.70
GF Value